Post Covid-19 Vaccination Development or Flare of ARD (PoCov-ARD)
Status
Conditions
Treatments
Details and patient eligibility
About
Many patients develop autoimmune diseases after covid-19 vaccination, whether related to the vaccination or not, is still under study. This study will describe potential flare of ARD after COVID-19 vaccination, whether it leads to activity or new MSK manifestations development.
Full description
-In this study: patients with known diagnosed rheumatic diseases who are vaccinated (one or full doses) of any type of COVID-19 vaccines will be enrolled. new ARD and prevalence of different MSK manifestations after covid-19 vaccinations also will be reported. The prevalence of flare of ARD after covid-19 vaccinations will be dteremined. Also we will compare between different types and doses of covid-19 vaccinations in inducing ARD or flares.
Study Design: Cross sectional study Target population: any patient with pre-existing received any vaccination against covid-19 visiting rheumatology outpatient clinic.
-any patient develops MSK manifestations after covid-19 vaccination. The disease activity sataus will be measured according to the type of rheumatic disease. For RA , disease activity score28 will be used, in lupus: SLEDAI, in Behcet : BDCAF, in SpA: BASDAI.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age above 18 years Vaccinated against covid-19 (one dose or fully vaccinated)
Exclusion criteria
Receiving other vaccine e.g influenza Less than 18 years old
Trial contacts and locations
Loading...
Central trial contact
Mervat Eissa, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal